** Memphasys MEM.AX soars as much as 57.1% to A$0.011, set for biggest intraday gain since August 18, 2022
** Stock hits highest since January 6
** Medical devices maker reports positive clinical trial results for its Felix sperm selection system
** Says results exceed industry benchmarks in sperm selection for assisted reproductive technology
** Stock logs busiest trading day since October 2018, with ~50.3 mln shares traded vs 30-day avg of ~1.8 mln
** MEM last up ~43%, extends YTD gains to 25%
(Reporting by Aaditya Govind Rao in Bengaluru)
((Aaditya.govindrao@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.